By univariate analysis, adenocarcinoma patients harboring EGFR mutations had DFS and OS significantly associated with clinical stage, tumor size, regional lymph node (LN) metastasis, adjuvant treatment, CEA, and Cyfra21-1 (Table 3). This evidence concerns the gene CEACAM5 and adenocarcinoma.